Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.430
-0.110 (-4.33%)
At close: Aug 28, 2026, 4:00 PM EDT
2.430
-0.001 (-0.02%)
After-hours: Aug 28, 2026, 7:48 PM EDT
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $2.08M in the quarter ending June 30, 2026, with 9.18% growth. This brings the company's revenue in the last twelve months to $6.49M, down -23.36% year-over-year. In the year 2025, Fate Therapeutics had annual revenue of $6.65M, down -51.24%.
Revenue (ttm)
$6.49M
Revenue Growth
-23.36%
P/S Ratio
44.86
Revenue / Employee
$40,317
Employees
161
Market Cap
291.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.65M | -6.99M | -51.24% |
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
| Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
| Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
| Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
| Dec 31, 2015 | 2.43M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
| Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
| Dec 31, 2011 | 1.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Invivyd | 58.37M |
| Lineage Cell Therapeutics | 13.08M |
| Opus Genetics | 9.86M |
| Cartesian Therapeutics | 1.48M |
| Vicore Pharma Holding AB | 412.09K |
FATE News
- 14 days ago - Fate Therapeutics reports Q2 EPS (25c), consensus (26c) - TheFly
- 14 days ago - Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo - TheFly
- 14 days ago - Fate Therapeutics intiates first patient in RECLAIM-LN trial - TheFly
- 14 days ago - Fate Therapeutics price target raised to $8 from $6 at Piper Sandler - TheFly
- 16 days ago - Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis - GlobeNewsWire
- 17 days ago - Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 17 days ago - Fate Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Fate Therapeutics Earnings release: Q2 2026 - Filings